Did These Stocks Catch Your Eye? (ZYME, NVTA)

(RTTNews) - The stocks on the move...

1. Zymeworks Inc. (ZYME)

Zymeworks is a clinical-stage biopharmaceutical company developing biotherapeutics, with a focus on immuno-oncology and other therapeutic areas.

The Company's lead asset is ZW25, which is under a:

-- Phase I trial as a monotherapy in patients with HER2-expressing solid tumors, including biliary tract cancer, colorectal cancer, gynecological cancers, and gastroesophageal adenocarcinoma. -- Phase II study in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Another product in the pipeline is ZW49, under a phase I trial in patients with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Zymeworks has licensed its technology platform to leading pharmaceutical and biotechnology companies to bring innovative therapies into clinical development.

In July of this year, Celgene Corp. selected a lead therapeutic candidate built using Zymeworks' proprietary Azymetric platform and exercised its option to a commercial license for which Zymeworks received a US$7.5 million payment.

Recent event:

On November 5, 2019, the Company reported financial results for the third quarter ended September 30, 2019.

The net loss for the three months ended September 30, 2019, widened to $30.5 million or $0.70 per share from $18.8 million or $0.59 per share in the same period of 2018. Revenue from partnerships for the recent third quarter was $7.9 million compared to $2.1 million in the same period of 2018.

The Company ended September 30, 2019, with cash of $335.1 million.

ZYME touched an all-time high of $38.30 in intraday trading on Tuesday, before closing at $38.29, up 2.93%.

2. Invitae Corporation (NVTA)

Invitae is a medical genetics company.

Early this month, the Company announced financial and operating results for the third quarter ended September 30, 2019.

For the third quarter of 2019, Invitae reported a net loss of $78.7 million or $0.82 per share compared to a net loss of $31.7 million or $0.45 per share in the third quarter of 2018. Non-GAAP net loss was $65.8 million in the third quarter of 2019, or a $0.69 non-GAAP net loss per share.

The Company derives revenue from test reports generated from its assays. Revenue in the third quarter of 2019 was $56.5 million compared to $37.4 million in the year-ago quarter.

Over 129,000 samples were accessioned in the third quarter of 2019, representing a 65% increase over the 78,000 samples in the third quarter of 2018. Gross profit in the third quarter of 2019 was $24.4 million compared to $16.9 million in the third quarter of 2018.

The Company ended September 30, 2019, with cash of $473.5 million.

NVTA closed Tuesday's trading at $19.40, up 6.24%. The stock is off 32% from its 52-week high of $28.75 recorded on August 7, 2019.